TRIPTODUR KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIPTODUR KIT (TRIPTODUR KIT).
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
| Metabolism | Metabolized by peptidases; not significantly metabolized by CYP450 enzymes. |
| Excretion | Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized. |
| Half-life | Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged. |
| Protein binding | Approximately 90-95% bound to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Vd is approximately 1.2-1.4 L/kg, indicating distribution into total body water and tissues. |
| Bioavailability | Intramuscular: 100% bioavailability (depot formulation). |
| Onset of Action | Intramuscular injection: Therapeutic effect on testosterone levels observed within 2-4 days; peak suppression of gonadotropins by 2 weeks. |
| Duration of Action | Single IM injection provides effective suppression of testosterone for 4 weeks, supporting monthly dosing. Effect on symptoms persists for 8-12 weeks post-injection due to prolonged release. |
| Molecular Weight | 615.72 |
3.75 mg intramuscularly once every 28 days.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | No clinical studies in hepatic impairment; use with caution and monitor closely. No specific Child-Pugh based recommendations. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and tolerability closely due to age-related decreased renal function. |
| 1st trimester | Contraindicated: Risk of fetal harm (pregnancy category X). |
| 2nd trimester | Contraindicated: May cause fetal harm. |
| 3rd trimester | Contraindicated: May cause fetal harm. |
Clinical note
Comprehensive clinical and safety monograph for TRIPTODUR KIT (TRIPTODUR KIT).
| Placental transfer | Active transport across placenta; high degree of transfer. |
| Breastfeeding | Excreted in breast milk; risk of serious adverse effects in infant. Discontinue nursing or drug. |
| Lactation Rating | L5 - Contraindicated |
■ FDA Black Box Warning
None
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to any componentEndometriosis with active pregnancy desire
| Precautions | Transient increase in serum testosterone during initial therapy may cause worsening of prostate cancer symptoms (tumor flare), Hyperglycemia and increased risk of diabetes, Cardiovascular events (myocardial infarction, sudden cardiac death) have been reported, QT interval prolongation, Bone density loss with long-term use |
| Food/Dietary | No specific food interactions. Avoid grapefruit products as they may alter drug metabolism; maintain a balanced diet. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | TRIPTODUR KIT (triptorelin pamoate) is contraindicated in pregnancy. First trimester exposure carries risk of spontaneous abortion and congenital anomalies due to anti-gonadotropic effects. Second and third trimester: continued use may cause fetal harm from hormonal disruption. |
| Fetal Monitoring | Monitor pregnancy status with serum β-hCG prior to each dose. During pregnancy, if exposure occurs, monitor fetal development via ultrasound and assess for congenital anomalies. |
| Fertility Effects | Reversible suppression of gonadotropin secretion, leading to anovulation and amenorrhea. Long-term use may delay return of fertility; generally reversible upon discontinuation. |
| TRIPTODUR KIT (triptorelin pamoate) is a long-acting gonadotropin-releasing hormone (GnRH) agonist for advanced prostate cancer. Monitor for tumor flare during first 2 weeks; consider antiandrogen coadministration. Assess serum prostate-specific antigen (PSA) and testosterone levels monthly. Warn patients about risk of hyperglycemia and diabetes. Contraindicated in women who are or may become pregnant. |
| Patient Advice | This injection is given once every 4 weeks or every 3 months by a healthcare professional. · You may experience a temporary worsening of symptoms (e.g., bone pain, urinary symptoms) in the first few weeks. · Report new or worsening pain, difficulty urinating, or blood in urine. · This medication may cause hot flashes, decreased libido, erectile dysfunction, and fatigue. · Do not become pregnant while on this treatment; use effective contraception. · Monitor blood sugar levels regularly; inform your doctor if you have diabetes. |